检测氨基末端脑钠肽前体在心力衰竭患者中的临床意义被引量：31

Clinical significance of N-terminal pro-brain natriuretic peptide in patients with heart failure

下载PDF

导出

摘要目的探讨心力衰竭(HF)患者血清N末端B型脑钠肽前体(NT-proBNP)水平的改变及其临床意义。方法采用金标法测定108例HF患者、40例健康对照者及45例HF患者经常规治疗后第3、10、20天血清NT-proBNP水平,并进行统计分析。结果 HF患者血清NT-proBNP水平高于健康对照组(P<0.05),且血清NT-proBNP水平随着病情的加重而升高(P<0.05);HF患者治疗后血清NT-proBNP水平逐渐下降(P<0.05)。结论血清NT-proBNP是可有效反映心功能状态的客观指标,对HF诊断、病情判断、疗效及预后评价有重要价值。 Objective To investigate the changes and clinical significance of serum N-terminal pro-brain natriuretic peptide（NT-proBNP）in patients with heart failure（HF）.Methods The serum NT-proBNP levels were measured by gold labeling immunoassay in 108 patients with heart failure,40 healthy controls and 45 patients on the 3rd,10th and 20th days after conventional treatment.All data were statistically analyzed.Results Serum NT-proBNP levels of patients groups were significantly higher than that of healthy controls（P〈0.05）,and increased with the severity of HF（P〈0.05）.Serum NT-proBNP levels of patients gradually declined on the 3rd,10th and 20th days after treatment（P〈0.05）.Conclusion Serum NT-proBNP level could be a powerful objective indicator reflecting the state of cardiac function,and have significant clinical value in the diagnosis,evaluation of pathogenetic condition,curative effect and prognosis of HF

作者王瑜余焰

机构地区重庆市中医院检验科

出处《国际检验医学杂志》 CAS 2011年第12期1324-1325,共2页 International Journal of Laboratory Medicine

关键词心力衰竭诊断 N末端B型脑钠肽前体 heart failure diagnosis N-terminal pro-brain natriuretic peptide

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献10

1Mair J,Hammerer Lercher A,Puschendorf B.The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure[J].Clin Chem Lab Med,2001,39(3):571-588.
2赵丽,吴学思,韩智红,胡荣,吕强.B型利钠肽检测对心力衰竭患者的临床评估[J].中华心血管病杂志,2004,32(1):51-52. 被引量：164
3汪芳,李卫,黄洁,王莉,边文彦,庞会敏,王洋,顼志敏,李一石.血浆N末端原脑利钠肽水平对慢性心力衰竭患者长期预后的预测价值[J].中华心血管病杂志,2006,34(1):28-32. 被引量：83
4Sudoh T,Kangawa K,Minamino N,et al A new natri2uretic peptide in porcine brain[J].Nature,1988,332(6159):78-81.
5Berendes E,Schmidt C,Van Aken H,et al.A-type and B-type2 natriuretic peptides in cardiac surgical procedures[J].Anesth Analg,2004,98(1):11-19.
6Mueller T,Gegenhuber A,Poelz W,et al.Biochemical diagnosis of impaired left ventricular ejection fraction-comparison of the diagnosis accuracy of brain natriuretic peptide(BNP)and amino terminal proBNP(NT-proBNP)[J].Clin Chem Lab Med,2004,42(1):159-163.
7周庭根,赵虎.临床微生物学[M].上海:上海科学技术出版社,2001.193-195.
8Meada K,Tsutamota T,Wada A,et al.Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction[J].Am Heart J,1998,135(4):825-832.
9李镛,顾学章.B-型利钠肽在肺科临床的应用[J].临床肺科杂志,2006,11(2):203-204. 被引量：24
10Verdiani V,Ognibene A,RutiliM S,et,al NT-proBNP reduction percentage during hospital stay predicts long-term mortality and readmission in heart failure patients[J].J Care diovasc Med(Hagerstown),2008,9(7):694-699.

二级参考文献27

1Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department(PRIDE) study. Am J Cardiol.2005 .95 :948-954.
2Pemberton C J, Yandle TG, Radenmker MT, et al. Amino-terminal proBNP in ovine plasma: evidence for enhanced secretion in response to cardiac overload. Am J Physiol, 1998, 275:1200-1208.
3Mancia G. Neurohumoral activation in congestive heart failure. Am Heart J, 1990,120:1532-1537.
4Yeo KT, Wu AH, Apple FS, et aL Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta, 2003, 338: 107-115.
5Tsutsmoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide levels as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Eur Heart J, 1999, 20:1799-1807.
6Omland T, Aakvaag A, Bonarjee WS,et aL Plasma brain natriuretic peptide as an indicator of left ventricular systolic dysfunction and long-term survival after acute myocardial infarction: comparion with plasma atrial natriuretic peptide and N-terminal proatria natriuretic peptide. Circulation, 1996,93 : 1963-1969.
7Mc Donagh T, Cunningham AD, Morrison CE, et al. Left ventricular dysfunction, natriuretic poptide, and mortality in an urban population. Heart,2001,86:21-26.
8Squire IB, O'Brien RJ, Demme B, et al. N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clin Sci,2004, 107:309-316.
9Richard MA, Nicholls GM, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin : new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation, 1998, 97 : 1921-1929.
10Bazzino O, Fuselli JJ, Botto F, et al. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J, 2004, 25:859-866.